Society guideline links: Prevention of meningococcal disease

Introduction — 

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately:

●(See "Society guideline links: Meningococcal disease".)

●(See "Society guideline links: Bacterial meningitis in adults".)

●(See "Society guideline links: Bacterial meningitis in infants and children".)

●(See "Society guideline links: Travel medicine".)

International

●World Health Organization (WHO): Meningococcal vaccines – Position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt (2024)

•WHO: Meningococcal A conjugate vaccine – Updated guidance (2015)

•WHO: Position paper on meningococcal vaccines (2011)

●WHO: Guideline on meningitis outbreak response in sub-Saharan Africa (2014)

Canada

●Public Health Agency of Canada (PHAC): Canadian Immunization Guide – Meningococcal vaccines (2015, updated 2024)

●National Advisory Committee on Immunization (NACI): An Advisory Committee Statement (ACS) on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure, update (2023)

●NACI: An Advisory Committee Statement (ACS) on the use of bivalent factor H binding protein meningococcal serogroup B (MenB-fHBP) vaccine for the prevention of meningococcal B disease (2019)

United States

●Centers for Disease Control and Prevention (CDC): Meningococcal disease – For health care providers

•Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy

•Clinical guidance for meningococcal disease

•Clinical overview of meningococcal disease

•Yellow Book 2024 – Health Information for International Travel: Meningococcal disease (published 2023)

•Epidemiology and Prevention of Vaccine-Preventable Diseases ("The Pink Book") – Meningococcal disease (2021)

●Advisory Committee on Immunization Practices (ACIP): Meningococcal vaccine recommendations

•Adult immunization schedule – Recommendations for ages 19 years or older, United States (2025)

•Child and adolescent immunization schedule – Recommendations for ages 18 years or younger, United States (2025)

•Recommendations on use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years – United States, 2023 (published 2024)

•Updated recommendations on new dosing interval and schedule for the Bexsero MenB-4C vaccine — United States (2024)

•Recommendations on meningococcal vaccination – United States (2020)

●American Academy of Pediatrics (AAP): Red Book – Meningococcal infections, update (2025)

Europe

●European Centre for Disease Prevention and Control (ECDC): Vaccine scheduler – Meningococcal disease: Recommended vaccinations

United Kingdom

●UK Health Security Agency (UKHSA): Meningococcal disease – Guidance, data, and analysis (2014, updated 2024)

●UKHSA: The Green Book – Immunisation against infectious disease: Meningococcal (2013, updated 2022)

Australia–New Zealand

●Australian Technical Advisory Group on Immunisation (ATAGI): The Australian Immunisation Handbook – Meningococcal disease